Vegamour is a premium, direct-to-consumer, clean hair wellness brand.

Jüsto is a leading vertically-integrated online grocery platform in Mexico.

Zoomin is a leading knowledge and content orchestration platform.

Biotheus is a clinical development stage company treating cancer and autoimmune diseases through next-generation therapeutics.

Coalition is a leading provider of cyber and commercial insurance, combining comprehensive insurance and cybersecurity tools to help businesses manage and mitigate cyber risk.

Equality Health is a leading provider of technology, services and support for value-based care, serving the Medicaid, Medicare and ACA Exchange populations.

CareMetx is a leading technology-enabled hub services company dedicated to improving patient access to specialty medications.

Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process, with a subsidiary portfolio supported by a centralized infrastructure, asset-centric R&D model and the Centessa management team.

Kalbe Genexine Biologics (“KGBio”) is an Indonesia-based joint venture between Kalbe Farma and Genexine. KGBio focuses on the in-licensing, clinical development, and manufacturing of biological products, especially in the area of immuno-oncology.

Evisort is an intelligent contract management platform that leverages proprietary AI to help enterprises categorize, search, and act on business-driving documents.

SPINS is a leading provider of data, analytics and technology for health and wellness-focused consumer packaged goods brands and retailers.

Albert is a financial services company that provides financial advice and automated savings guidance to consumers.

Open Farm is a premium pet food brand that provides high-quality nutrition for pets and supports the ethical and sustainable sourcing of ingredients.

Bolt is a leading provider of optimized checkout, payments and fraud technology to online retailers.

Gen II is a leading independent U.S. private capital focused fund administrator.

Pharvaris is a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE), a rare and potentially life-threatening genetic condition.